![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 30, 23106-23112, July 28, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Surgical Oncology/Molecular and Cellular
Oncology and the Breast Cancer Research Program, the University of
Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Received for publication, July 15, 1999, and in revised form, February 25, 2000
14-3-3 sigma, implicated in cell cycle arrest by
p53, was cloned by expression cloning through
cyclin-dependent kinase 2 (CDK2) association. 14-3-3 sigma
shares cyclin-CDK2 binding motifs with different cell cycle regulators,
including p107, p130, p21CIP1, p27KIP1,
and p57KIP2, and is associated with cyclin·CDK complexes
in vitro and in vivo. Overexpression of 14-3-3 sigma obstructs cell cycle entry by inhibiting cyclin-CDK activity in
many breast cancer cell lines. Overexpression of 14-3-3 sigma can
also inhibit cell proliferation and prevent anchorage-independent
growth of these cell lines. These findings define 14-3-3 sigma as a
negative regulator of the cell cycle progression and suggest that it
has an important function in preventing breast tumor cell growth.
Cyclin-dependent kinases
(CDKs)1 are responsible for
the transitions of the eukaryotic cell cycle and are tightly regulated by extra- and intracellular signals. They act in concert with their
regulatory subunits, the cyclins, to facilitate the cell cycle
progression. The cell cycle regulatory machinery is controlled by both
positive and negative regulators. Cyclin-dependent kinases (CDKs) and their cyclin partners are positive regulators or
accelerators that help cell cycle progression. The recently
characterized cyclin-dependent kinase inhibitors (CKIs) are
important negative regulators that act as brakes to stop cell cycle
progression in response to regulatory signals (1). Two families of CKIs
have been characterized based on the specificity of interaction with
CDKs and sequence homology. The CIP/KIP family, which shares homology
at the N-terminal CDK inhibitory domain, includes
p21CIP1/WAF1 (2-5), p27KIP1 (6,
7), and p57KIP2 (8, 9). They interact with the cyclin·CDK
complexes and inhibit the kinase activity of cyclin A-CDK2, cyclin
D-CDK4, and cyclin E-CDK2. Overexpression of CIP/KIP inhibitors in
cells can cause G1 arrest, suggesting that they
preferentially target G1 cyclin·CDK complexes. The INK4
family includes p15 (INK4b) (10), p16 (INK4a) (11), p18 (INK4c) (12),
and p19 (INK4d) (13). The INK4 family recognizes CDK4 and CDK6 but not
CDK2 and may cause G1 arrest of the cell cycle by competing
with cyclin D for binding with CDK4. Because the cell cycle regulatory
machinery is such a complex system, it seems possible that more cell
cycle regulators have yet to be discovered. Insights into the detailed regulation of the cell cycle machinery will help us understand the
signals that render cells oncogenic. In order to understand the basic
cell cycle regulatory machinery, we used an expression cloning method
to search for CDK2-associated proteins and isolated a 14-3-3 protein.
The 14-3-3 proteins comprise a family of highly conserved acidic
proteins, and there are at least seven different mammalian isoforms.
Several activities have been ascribed to these proteins, including
signal transduction of Raf-1 (14, 15) and cell cycle regulation (16,
17). However, the molecular mechanism behind cell cycle regulation has
remained elusive. First, 14-3-3 epsilon and 14-3-3 beta have been
isolated in a yeast two-hybrid screen designed to identify proteins
that interact with the human CDC25A and CDC25B phosphatases. They bind
to CDC25 but do not affect the phosphatase activities of CDC25 (18).
Second, in a yeast two-hybrid screen designed to identify
Wee1-associated proteins, the 14-3-3 zeta has been found to interact
with the Wee1 kinase, which plays a key role in cell cycle progression
by inactivating cyclin-dependent kinases (19). However, the
binding of 14-3-3 zeta to Wee1 does not change the activity of Wee1
(19). Third, 14-3-3 has been shown to interact with polyoma middle T
antigen (20) involved in cell proliferation, but it remains to be
elucidated how regulation of 14-3-3 protein contributes to the
development of neoplasia. Fourth, in yeast, two checkpoint genes,
rad24 and rad25, encode 14-3-3 protein homologues
that together provide a function that is essential for cell
proliferation (16). The roles of RAD24 and RAD25 in regulating the
activity of Chk1 or CDC25 in determining the progression of mitosis in
response to DNA damage are not all clear (21, 22). Finally, 14-3-3 sigma (human mammary epithelial marker 1 or HME1) is expressed in
epithelial cells, and its expression is dramatically low in human
mammary carcinoma. However, its role in neoplastic formation is not
understood (23). Furthermore, 14-3-3 sigma is induced by p53 in
response to gamma irradiation and other DNA-damaging agents (24).
14-3-3 sigma induction results in a G2 arrest through an
uncharacterized mechanism (24). Together, these observations imply that
14-3-3 proteins play important roles in cell cycle and that different 14-3-3 isoforms may bind to specific proteins for executing its biological function in cell cycle progression. Here, we describe the
isolation, molecular cloning, and characterization of a CDK-associated protein 14-3-3 sigma. We show that 14-3-3 sigma could bind CDK2, CDC2,
and CDK4 and emerges as a new class of CDK inhibitor.
Expression Cloning of 14-3-3 Sigma cDNA--
We prepared the
FLAG-CDK2 following the procedure described before (8). Briefly, a
PCR-generated NdeI-BamHI fragment of the human
CDK2 cDNA containing the full-length coding region was subcloned
into pET21a (Novagen), yielding a construct that encodes CDK2 with a
FLAG tag sequence. Recombinant FLAG-CDK2 carrying the heart muscle
kinase phosphorylation site was phosphorylated in vitro by
protein kinase A with [ In Vitro Association of 14-3-3 Sigma and CDK Proteins--
A
PCR-generated NdeI-BamHI fragment of the mouse
14-3-3 sigma cDNA containing the full-length coding region was
subcloned into pET21a (Novagen) to yield a construct that encodes
14-3-3 sigma with a FLAG tag sequence. The protein was expressed in
BL21(DE3), and FLAG-tagged proteins were prepared as described
previously (8), except that proteins were immobilized on the beads
without elution. Baculoviral proteins containing cyclins and CDKs were prepared by following the method described before (26). Cyclin D2 and
CDK4 complex, cyclin B and CDC2 complex, or cyclin E and CDK2 complex
was formed by preincubating in activating buffer (30 mM
HEPES, 7.5 mM MgCl2, 40 mM
phosphocreatine, 0.2 mg phosphocreatine kinase, 0.03 mM
ATP). A T7 RNA polymerase-driven pET vector containing the coding
region of the mouse cyclin E or CDK2 cDNA was transcribed in
vitro and translated using a TNT kit (Promega). These products were labeled with [35S]methionine. These complexes, CDK,
or the products translated in vitro were then incubated with
the immobilized FLAG-tagged 14-3-3 sigma. After extensive washing in
Nonidet P-40/RIPA buffer, the retained protein complexes were
resuspended in SDS sample buffer. The complexes were resolved in
SDS-polyacrylamide gel electrophoresis, followed by hybridization with
CDK2 (PharMingen), CDK4 (PharMingen), and CDC2 antibody (Upstate
Biotechnology Inc.) or by fluorography.
In Vivo Association of 14-3-3 Sigma with CDK--
MCF-7, HER-18,
MDA-MB-468, MDA-MB-435, and MDA-MB-361 were kindly provided by Dr.
Mien-Chi Hung and grown to 80% confluence. The cells were then
infected with Ad-HME1 in serum-free media for 1 h. Complete media
were added, and the cells were harvested 48 h later. The cells
were lysed in RIPA buffer (100 mM NaCl, 20 mM
Tris, pH 8.0, 1 mM EDTA, pH 8.0, 0.5% Triton X-100, 0.5% Nonidet P-40) and quantified with a Bio-Rad kit following the conditions suggested by the manufacturer. Equal amounts of total protein were immunoprecipitated with anti-CDK2 (1:1000) for 1 h
followed by incubation with protein A beads for 30 min. After washing
with lysis buffer, the proteins were loaded onto a 12% SDS-polyacrylamide gel and subjected to electrophoresis.
Electrophoresed proteins were transferred to an Immobilon membrane
(Millipore, Bedford, MA) and probed with anti-HA monoclonal antibody
(12CA5, Babco). Immunocomplexes were visualized by chemiluminescence
(ECL kit, Amersham Pharmacia Biotech) using goat anti-mouse IgG
antibodies coupled with horseradish peroxidase (Amersham Pharmacia Biotech).
The CDK-associated Histone H1 Kinase Assay--
The cells were
infected with Ad-HME1 in serum-free media for 1 h. Complete medium
was added, and the cells were harvested 48 h later. The cells were
lysed in RIPA lysis buffer (100 mM NaCl, 20 mM
Tris, pH 8.0, 1 mM EDTA, pH 8.0, 0.5% Triton X-100, 0.5%
Nonidet P-40) and quantified. 500 µg of cell lysate was
immunoprecipitated with anti-CDK2 antibody (PharMingen) or anti-CDC2
antibody (PharMingen). The immunoprecipitates were assayed for histone
H1 kinase activity as described previously (8).
MTT, Tridium-Thymidine Incorporation, and Soft Agar Colony
Formation Assays--
MCF-7, HER-18, and MDA-MB-361 cells were
infected with either Ad-HME1 or Ad-
A tridium-thymidine incorporation assay was performed using the
same three cell lines and infection method as mentioned previously. Ten thousand cells per well were seeded for each cell line and type of
infection in a 96-well plate. Six hours later, 0.2 µCi/well of
tridium-thymidine was added and incubated for 16 h. Cells were lysed with 200 µl of 0.1 N KOH, and lysates were
collected using the harvester (Tomtec). Tridium-thymidine incorporation
was quantitated with the beta plate liquid scintillation counter
(Amersham Pharmacia Biotech).
Soft agar colony assays were performed on the same three cell lines and
under the same infection conditions. The following day, 2000 cells per
well mixed in a 0.35% agarose/complete media suspension were seeded
onto 0.7% agarose/complete media bottom layer. Three weeks later, 100 µl per well of p-iodonitrotetrazolium violet (1 mg/ml,
Sigma) was added for 16 h before photographed.
Flow Cytometry--
Indicated breast cancer cell lines (MCF-7,
HER-18, MDA-MB-453, and MDA-MB-468) were infected with or without
Ad-HME1 (m.o.i. = 10). Forty-eight hours after infection, cells were
sorted, and their DNA content was analyzed by flow cytometry, all as
described (7).
Immunofluorescence--
NIH3T3 cells (2 × 105)
were seeded onto chamber slides (Nunc) and infected without or with
Ad-HME1 (m.o.i. = 10). R1b/L17 cells were transfected with pCMV5
plasmid containing FLAG-tagged HME1, FLAG-tagged HME1 (NES),
T7-tagged-CDK2, or with empty vector. FLAG-tagged-HME1 (NES) is the NES
mutant with point mutations (I205A and L208A) at the NES sequence
(STLIMQLLRDNLTLW). This mutant was constructed by PCR mutation.
T7-tagged CDK2 was constructed by PCR cloning to contain the T7 gene 10 leader peptide tag sequence (MASTGGQQMG). Twenty-four hours after
infection or transfection, 2 × 105 cells were seeded
onto tissue culture chamber slide (Nunc). Two days later, cells were
fixed with methanol/acetone (1:1 v/v) and stained for 1 h with
rabbit anti-CDK2, rabbit anti-CDC2 antibodies (Santa Crutz), mouse
anti-FLAG monoclonal antibody (Sigma), or mouse anti-T7 monoclonal
antibody (Novgen), followed by 30-min exposures to anti-rabbit
Cy3-conjugated or anti-mouse fluorescein isothiocyanate-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories). Cells were
then incubated with 0.1 µg/ml of 4,6-diamidino-2-phenylindole (DAPI)
(Sigma) to stain the nuclei. Immunofluorescence was detected using a
BX50 Fluorescent microscope (Olympus).
Expression Cloning of 14-3-3 Sigma--
The mouse 14-3-3 sigma
gene was identified during a search for CDK2-associated proteins using
an expression cloning method to screen a mouse 16-day embryonic
cDNA library (27). Several clones were identified and sequenced. A
GenBankTM search revealed that, at the amino acid level,
one clone showed significantly high homology to human 14-3-3 sigma or
HME1 (Human mammary epithelium
marker 1) (23) and is the mouse ortholog of 14-3-3 sigma. The mouse
14-3-3 sigma (MME1) cDNA had an open reading frame of 744 base
pairs, and it encodes a predicted protein of 248 amino acids. The human
and mouse 14-3-3 sigma amino acid sequences are highly related, showing
~96% identity (Fig. 1A). Sequence analysis revealed an important feature of a leucine-rich nuclear exporting signal (NES) located at amino acids 202-216 (STLIMQLLRDNLTLW) that plays an important role in cell cycle regulation (22).
14-3-3 Sigma Contains the Cyclin-CDK Binding Motif--
Since we
identified mouse 14-3-3 sigma using CDK2 as a bait through expression
cloning, we compared the cyclin-CDK binding domain of all the important
cell cycle regulatory proteins, including p27KIP1,
p57KIP2, p21CIP1, p107, p130, and found that
there is a consensus cyclin-CDK binding sequence
(ZRXL, where Z and X are
basic amino acids) that can be deduced in these proteins as shown in
Fig. 1B. Structure determination of p27KIP1 has
indicated that peptides around the ZRXL region are very
critical for CDK binding (28). Therefore, 14-3-3 sigma is likely to use this CDK binding motif to interact with various CDKs.
14-3-3 Sigma Binds Cyclin-dependent Kinases--
To
confirm further the binding of 14-3-3 sigma to cyclin-CDK2, recombinant
FLAG-tagged 14-3-3 sigma protein was purified by M2 monoclonal
antibody-Sepharose and used for in vitro biochemical binding
assays. As shown in Fig. 2, 14-3-3 sigma
can bind to CDK2, CDK4, cyclin A/CDK2, cyclin B/CDC2, cyclin E/CDK2,
and cyclin D2/CDK4 specifically. 14-3-3 sigma also binds to in
vitro translated cyclin E or CDK2. In order to confirm that 14-3-3 sigma interacts with CDK in vivo, we infected cells with
recombinant adenovirus overexpressing HA-tagged 14-3-3 sigma, and we
found that both CDC2 and CDK2 associated with 14-3-3 sigma, as
demonstrated in the detection of CDK2 or CDC2 in the anti-HA
immunoprecipitation complex (Fig. 3).
Since CDKs are activated by their regulatory cyclins, we then tested
the role of 14-3-3 sigma in this dynamic activating process. Affinity
purified 14-3-3 sigma was used to test the binding character during the
activating process of CDK2 by cyclin E. The data show that 14-3-3 sigma
binds both active and inactive forms of CDK (Fig. 2E). These
results provide evidence that 14-3-3 sigma does not block CDK
activation, which is different from KIP1. KIP1 binds preactive cyclin
E·CDK2 complexes and prevents Thr160 phosphorylation and
activation of CDK2 (7).
CDK Inhibitory Activity--
Most CDK-associated proteins can
either negatively or positively regulate the activity of the CDKs. To
investigate if 14-3-3 sigma can regulate the activity of the CDKs
through protein association, we overexpressed 14-3-3 sigma in various
cell lines by virus gene transfer (24), and we examined whether 14-3-3 sigma regulates the activity of CDKs. Recombinant 14-3-3 sigma
adenovirus (Ad-HME1) was used to infect breast cancer cells under
conditions in which the majority of the cell population was infected
(m.o.i. = 10). The activity of both CDK2 and CDC2 was inhibited by the
expression of 14-3-3 sigma as demonstrated in CDK2/CDC2-associated
histone H1 kinase assays (Fig. 4). Also,
immunoblotting bands demonstrate that when these cells were infected
with Ad-HME1, HME1 associated with more than 95% of endogenous CDK2 or
CDC2 as quantitated by PhosphorImager Imagequant program (data not
shown), suggesting that 14-3-3 sigma can bind to most of the CDK2/CDC2
to inhibit their activities. All breast cancer cell lines tested were
sensitive to the inhibitory activity of 14-3-3 sigma regardless of p53, Rb (retinoblastoma protein), or HER-2/neu status. These results provided evidence that 14-3-3 sigma can physically associate with CDKs
and inhibit their activities. The inhibitory activity is also observed
in a cell line with non-epithelial origin (NIH3T3) that does not
express 14-3-3 sigma (data not shown).
14-3-3 Sigma Overexpression Inhibits Cell Proliferation and
Anchorage-independent Growth of Breast Cancer Cells--
The fact that
14-3-3 sigma can inhibit CDK activity suggests that 14-3-3 sigma may
inhibit cell proliferation by cell cycle arrest. To determine if 14-3-3 sigma could inhibit cell proliferation, we assessed its inhibitory
effect by MTT assay (29) and flow cytometry. Cell cycle analysis of
several breast cancer cell lines infected with recombinant 14-3-3 sigma
adenovirus by fluorescence-activated cell sorter demonstrated that
14-3-3 sigma has an effect on G2/M progression (Table
I). Three breast cancer cell lines
(MDA-MB-361, MCF7, and HER-18) were infected with recombinant 14-3-3 sigma adenovirus and assayed for live cells every 24 h.
Overexpression of 14-3-3 sigma markedly decreased the viable cell
number during a 7-day growth period as indicated by the decrease of
A570 reading (Fig.
5A). In a parallel virus
infection assay, the cells infected with adenovirus expressing
14-3-3 sigma was originally characterized as a molecule that was
down-regulated in transformed breast carcinoma cell lines (23),
suggesting that the activity of 14-3-3 sigma plays a pivotal role in
the transformation. To evaluate the effect of 14-3-3 sigma on the
transformation potency of the breast cancer cells, we performed the
soft agar colony formation assays. As shown in Fig.
6, breast cancer cell lines (MCF-7 and
HER-18) that received recombinant 14-3-3 sigma adenovirus had a
dramatic decrease in the number of colonies formed after 3 weeks (Fig.
6). The cells infected with adenovirus expressing 14-3-3 Sigma Inhibits Nuclear Accumulation of CDK2 and
CDC2--
To support the hypothesis that interaction of 14-3-3 sigma
and CDK proteins could have a physiological role, subcellular
localization of these proteins was analyzed. As shown in Fig.
7, 14-3-3 sigma caused a decrease in the
nuclear staining for both CDK2 and CDC2 compared with the controls.
These results indicate that 14-3-3 sigma can sequester CDK2 and CDC2
from the nucleus, thereby preventing the activity of CDK2 and CDC2.
Because 14-3-3 sigma contains a leucine-rich nuclear exporting signal
at amino acid residues 202-216 (Fig. 1), we determined whether the
nuclear accumulation of CDK2/CDC2 is mediated by the nuclear exporting
activity of 14-3-3 sigma. An NES mutant of 14-3-3 sigma was constructed
by mutating the leucine-rich NES sequence with alanine (I205A and
L208A). Immunolocalization studies showed that wt 14-3-3 sigma was
detected in the cytoplasm, whereas the NES mutant of 14-3-3 sigma was
mainly detected in the nucleus (Fig. 8,
A and C). We also found that CDK2 is distributed in the cytoplasm in the presence of wt 14-3-3 sigma (Fig.
8G), but CDK2 remains in the nucleus when coexpressed with
the NES mutant of 14-3-3 sigma (Fig. 8I). CDK2 transfection
was used as a control and was demonstrated as a nuclear protein (Fig.
8K). DAPI is used to stain the nuclei. These results
demonstrated that the binding of 14-3-3 sigma to CDK can cause the
sequestration of CDK2 and CDC2 into the cytoplasm, and the NES of
14-3-3 sigma is required for this biological function.
New Class of CKI--
In a search for CDK2-associated proteins, we
have identified a 14-3-3 protein, 14-3-3 sigma, that specifically
associates with CDK2. 14-3-3 proteins are important and highly related
dimeric factors found in eukaryotic organisms, including yeast,
mammals, Drosophila, and plants (17). Members of the 14-3-3 family are involved in regulating the activities of tyrosine and tryptophan hydroxylases and protein kinase C, exocytosis, transcriptional activities, and the cell cycle (17). Here we demonstrated the specific
interaction between CDKs and 14-3-3 sigma, and we characterized the
biological functional role of the interaction in cell cycle progression. Interestingly, one CDK-like protein PCTAIRE-1 was shown to
interact with several isoforms of 14-3-3, including eta, tau, and zeta
isoforms (30). However, the significance of these interactions in cell
cycle regulation remains to be determined. Sequence analysis showed
that the 14-3-3 sigma protein is highly conserved with 96% identity in
human and mouse. Its distinctive feature is a cyclin-CDK binding motif
that is shared by many cyclin-CDK-binding proteins (Fig. 1), including
CIP/KIP family members. In vitro binding experiments confirm
that 14-3-3 sigma binds to various cyclin·CDK complexes (Fig. 2).
Interestingly, purified 14-3-3 sigma cannot inhibit cyclin-CDK activity
(data not shown) in vitro although overexpression of 14-3-3 sigma in the cells can inhibit CDK2/CDC2-associated kinase activity
(Fig. 4) and cell cycle progression (Fig. 5), suggesting that a
biological environment is required to assay its CDK inhibitory
activity. Because it binds and inhibits various cyclin-CDKs to regulate
cell cycle progression and cell proliferation, 14-3-3 sigma emerges as
a new class of CKI.
CDK Inactivation and Growth Inhibition--
We showed that 14-3-3 sigma affects the subcellular localization of CDK2 and CDC2 to inhibit
their accumulations in the nucleus, thus preventing the activation of
CDK2/CDC2 in the nucleus. This mislocation of CDK2 and CDC2 in the
cytoplasm can cause inhibition of their biological activities (31).
Sequence analysis revealed a leucine-rich NES-like sequence
(202STLIMQLLRDNLTLW212) in the 14-3-3 sigma. Indeed, we showed that 14-3-3 sigma can bind CDK proteins and
sequester them in the cytoplasm (Fig. 7) through the nuclear exporting
activities. The nuclear exporting sequence is involved in the
sequestration of CDK2 since the NES mutant of 14-3-3 sigma cannot
sequester the CDK2 into the cytoplasm (Fig. 8). Other 14-3-3 proteins
have similar characteristics to export their target proteins to the
cytoplasm, thus preventing their activities at the nucleus. For
example, CDC25 is phosphorylated by Chk1 (32) or Chk2 (33) to create a
binding site in CDC25 for 14-3-3 proteins and is exported by
Rad24/Rad25 (also 14-3-3 proteins) in response to DNA damage (22),
thereby inhibiting the activity of CDC25 and causing G2/M
arrest. But it also remains to be determined which kinase is
responsible for the serine phosphorylation on CDK2/CDC2 since targeted
proteins of 14-3-3 required serine phosphorylation before binding to
14-3-3 (34). We demonstrated that 14-3-3 sigma can affect cell cycle
distribution at the G2/M (Table I), which highlights its
role at the G2/M control. The significance of the role of
14-3-3 sigma in inhibiting CDK2 activity and CDK2 nuclear accumulation
remains to be determined in terms of cell cycle distribution and
checkpoint control. However, both inhibition of CDC2-associated kinase
activity and sequestering of CDC2 into the cytoplasm can account for
its role in G2/M control.
Sequence analysis of human CDK2 reveals that there are two possible
14-3-3-binding sites located at the C-terminal region of CDK2
(GVTS229MP and YKPS236FP), which share a homologous sequence to what
has been predicted as the 14-3-3 sigma-binding sites (35). Therefore,
it is possible that 14-3-3 sigma may bind to this region to regulate
CDK activities and cell cycle progression. Our data show that
overexpression of 14-3-3 sigma in vivo could bind and inhibit the activities of CDK2 and CDC2 and render cells unable to
reach cell cycle transition. In this aspect, it is functionally similar
to the CIP/KIP family members. The strong reduction in the growth rate
and the decrease in [3H]thymidine incorporation caused by
14-3-3 sigma expression are also consistent with a role of 14-3-3 sigma
as a negative regulator of cell cycle. Through IR, 14-3-3 sigma was
shown to be a mediator of p53 growth-inhibitory signaling (24). As
cells received ionizing radiation, p53 quickly induced 14-3-3 sigma
expression within 2 h, and this induction led to G2/M
arrest (24). The mechanism behind this 14-3-3 sigma-induced cell cycle
arrest is not clear, although it was proposed that 14-3-3 sigma may
sequester CDC25C to cause G2 arrest (24) based on the
observations that other 14-3-3 isoforms can interact with CDC25 (18,
36, 37). It remains to be elucidated if 14-3-3 sigma can interact with
CDC25 directly to block G2/M progression in response to DNA
damage. Our data show that 14-3-3 sigma can directly bind and sequester CDC2 into the cytoplasm to inhibit its activity required for
G2/M progression, which may contribute to IR-induced
p53-mediated G2/M arrest.
Inhibition of Cell Transformation--
After 14-3-3 sigma was
cloned, it was determined that the expression level is significantly
reduced both in v-Ha-Ras transformed mammary epithelial cells and
mammary carcinoma cells (23). Furthermore, expression of 14-3-3 sigma
was also reduced in SV40-transformed human keratinocytes compared with
primary cells (38). Finally, the transcript of 14-3-3 sigma was
down-regulated in head and neck squamous cell lines in comparison with
keratinocytes (39). Together these observations support the idea that
loss of its expression contributes to malignant transformation. Recent
studies in breast carcinomas and colon cancer suggested that p27
expression is decreased when cells become tumorigenic (40-42). These
observations lend further support to the concept that the CDK activity
controls cell proliferation and is involved in the development of human cancer. The decreased expression of HME1 in neoplastic mammary cells is
reminiscent of p27 down-regulation in breast cancer. We hypothesize
that the expression of 14-3-3 sigma, like the function of
p27KIP1, is one of the mechanisms cells employ to ensure
the maintenance of a nonproliferative state. The fact that 14-3-3 sigma
suppressed the anchorage-independent growth of some breast cancer cell
lines (Fig. 6) supports the idea that loss of 14-3-3 sigma function correlates with cell transformation. Taken together, these results suggest that a reduction of 14-3-3 sigma plays an important role in
cell transformation. Most significantly, fluorescence in
situ hybridization analysis of metaphase chromosomes with a 14-3-3 sigma probe showed that 14-3-3 sigma was localized to chromosome 1p35
(24) where high percentages of loss of heterozygosity (43) were seen in
different solid tumors including breast tumors (44). Also, on the basis
of loss of heterozygosity and other data, 1p35 may harbor a tumor
suppressor gene (45). The negative regulator role of 14-3-3 sigma in
cell cycle progression and cell transformation suggests that 14-3-3 sigma could be the candidate for this tumor suppressor gene in the 1p35
region. Further investigation of the expression pattern and gene
function of 14-3-3 sigma in tumors will shed light on its potential
role as a tumor suppressor.
In summary, our characterization of 14-3-3 sigma as a CDK inhibitor
will facilitate the study of its regulation and function in the cell
cycle, its possible role as a tumor suppressor, and its possible
implication in the gene transfer for p53-mutated cancer cells.
We thank Drs. Hermeking and Vogelstein for
valuable reagents; Drs. David Mentor and John Clifford for microscope
help; Drs. Mein-Chie Hung, Ming-Jer Tsai, Sophia Tsai, and GiGi Lozano
for critical reading; Rachel Z. Tsan, and Dr. Russell Berman for
technical help.
*
This work was supported by the William G. Mcgowan Charitable
Foundation and by a Physician Referral Service grant from the University of Texas M. D. Anderson Cancer Center.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF152893.
§
Recipient of the Fleming and Davenport research award. To whom
correspondence should be addressed: Box 18, the University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-792-8741; Fax: 713-796-6059; E-mail:
mhlee@notes.mdacc.tmc.edu.
Published, JBC Papers in Press, April 14, 2000, DOI 10.1074/jbc.M905616199
The abbreviations used are:
CDKs, cyclin-dependent kinases;
CKIs, cyclin-dependent kinase inhibitors;
PCR, polymerase chain
reaction;
HA, hemagglutinin;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
DAPI, 4,6-diamidino-2-phenylindole;
NES, nuclear exporting signal;
m.o.i., multiplicity of infection;
Ad, adenovirus;
wt, wild type.
Association of the Cyclin-dependent Kinases and
14-3-3 Sigma Negatively Regulates Cell Cycle Progression*
,
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP following the
procedure previously described (25). The phosphorylated CDK2 were used
to screen a mouse 16-day embryonic library that is a T7 RNA
polymerase-driven
EXlox mouse embryonic cDNA library (Novogen).
At least 10 × 106 clones were screened. Several
positive clones were sequenced, and one positive clone contained
full-length c-DNA of mouse 14-3-3 sigma.
-galactosidase and compared with
noninfected controls. The cells were harvested 48 h later, washed
with phosphate-buffered saline, and trypsinized. By using the cell
counter, 3000 cells/well (96 well plate) were seeded for each cell line
and type of infection. This was replicated 7 times for serial time
point measurements. Starting the following day and continuing daily for
a total of 7 days, 50 µl of 4.8 mM MTT was added per well
for 2 h. The cells were lysed with 200 µl of 100%
Me2SO, and the absorbance at 570 nm reading was obtained
using the 96-well plate reader (Ceres UV900C, Bio-Tek instruments
Inc.). The absorbance is directly proportional to the number of cells.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (36K):
[in a new window]
Fig. 1.
Mammalian 14-3-3 sigma sequences and
cyclin-CDK2 recognition motif. A, alignment of 14-3-3 sigma amino acid sequences deduced from cDNA of mouse (MME1) and
human (HME1). Identical amino acids are indicated by
ellipses. The region of amino acid 202-216 contains a
leucine-rich NES sequence. B, identification of a
cyclin-CDK2 recognition motif present in MME1. Shown is the sequence
alignment of cyclin-CDK2 binding motifs from different cell cycle
regulators, including p107, p130, p21CIP1,
p27KIP1, p57KIP2, and MME1. HME1 contains the
exact recognition motif. p21CIP1 contains two such motifs,
one at the N terminus (p21N) and one at the C terminus
(p21C). The consensus sequence can be represented as
(ZRXL), where Z and X, in
most cases, are basic amino acids.

View larger version (32K):
[in a new window]
Fig. 2.
CDK association by 14-3-3 sigma in
vitro. A-C, 14-3-3 sigma associated with
CDC2, CDK2, and CDK4. Recombinant FLAG-tagged 14-3-3 sigma was
immobilized on the M2 beads. Insect cell lysates containing CDK2, CDC2,
CDK4, and cyclins A, B, and D2 were incubated with the immobilized
FLAG-tagged 14-3-3 sigma. After extensive washings, the retained
protein complexes were detected by hybridization with CDK2, CDK4, and
CDC2 antibodies, respectively. Immobilized FLAG-tagged 14-3-3 sigma
beads were used as negative controls for each experiment (1st
lane of each figure). Insect cell lysates containing CDK2, CDC2,
or CDK4 were used as positive controls for immunoblotting (last
lane of each figure). D, 14-3-3 sigma associated with
in vitro translated cyclin E and CDK2. FLAG-tagged 14-3-3 sigma was bound to M2-Sepharose beads and was incubated with T7 RNA
polymerase driven in vitro translated
[35S]Met-labeled cyclin E or CDK2.
indicates the
in vitro translated empty vector products and was used as
negative binding controls. In vitro translated cyclin E and
CDK2 proteins that were not incubated with FLAG-tagged 14-3-3 sigma
beads were shown. E, 14-3-3 sigma binds to two forms of
CDK2. FLAG-tagged 14-3-3 sigma was bound to M2-Sepharose beads and was
incubated with equal amount of recombinant CDK2 (20 µg) plus an
indicated amount of recombinant cyclin E (5 µg/µl). In the absence
of other proteins, 14-3-3 sigma-bound Sepharose is used as a negative
control. Cdk2* indicates the faster migrating form of CDK2
that corresponds to CDK2 phosphorylated at Thr160 and is
the active form of CDK2.
![]()
View larger version (16K):
[in a new window]
Fig. 3.
Mammalian expression of 14-3-3 sigma and its
association with CDK2 and CDC2 in vivo.
Ad-HME1-HA (+) and Ad-
-galactosidase (
) were used to infect
indicated breast cancer cell lines. Ad-HME1- and
Ad-
-galactosidase-infected cell lysates were immunoprecipitated by
anti-CDK2 or anti-CDC2 antibody (PharMingen), resolved in
SDS-polyacrylamide gel electrophoresis, and immunoblotted with anti-HA
antibody (12CA5, Babco) to observe the association between 14-3-3 sigma
and CDK2 or CDC2.

View larger version (22K):
[in a new window]
Fig. 4.
14-3-3 sigma inhibits CDK2- and
CDC2-associated histone H1 kinase activities. Indicated equal
amounts of cell lysates infected with Ad-HME1-HA (+) or
Ad-
-galactosidase (
) were assayed for CDK2-or CDC2-associated
histone H1 (HH1) kinase activity. The phosphorylated histone H1
substrates are shown.
-galactosidase (Ad-
-galactosidase) grew normally as the cells
that did not receive 14-3-3 sigma. Also, the rate of
[3H]thymidine incorporation into DNA was reduced by half
in cells infected with 14-3-3 sigma as compared with cells receiving no 14-3-3 sigma (Fig. 5B). Collectively, these results suggest
that 14-3-3 sigma overexpression can prevent cell proliferation.
Effect of Hme1 on cell cycle distribution

View larger version (34K):
[in a new window]
Fig. 5.
Overexpression of 14-3-3 sigma blocks cell
growth and cell cycle entry into S phase. The Ad-HME1-HA or
Ad-
-galactosidase (Ad-b-gal) was used to infect MCF7,
HER-18, and MDA-MB-361 cell lines. Non-infected cells were used as
controls. A, inhibitory effect of HME1 on cell growth. The
cells were estimated by MTT assay every day for a total of 7 days. The
results were expressed as the value of A570
reading. The absorbance is directly proportional to the number of
cells. Bars, S.D. B, 14-3-3 sigma blocks cell
cycle entry into S phase. [3H]Thymidine incorporation
assays were conducted after 48 h infection. The experiments were
repeated for three times. Data are expressed as percentage of
[3H]thymidine incorporation relative to the controls of
each cell line.
-galactosidase
showed almost the same number of colonies as the cells that did not
receive 14-3-3 sigma. Taken together, our data indicated that the
transformed phenotypes of breast cancer cells can be reversed by
overexpression of 14-3-3 sigma.

View larger version (73K):
[in a new window]
Fig. 6.
14-3-3 sigma decreased the transformation
potency of the breast cancer cells. Two breast cancer cell lines,
MCF7 and HER-18, were measured for their transformed properties in the
presence of overexpression of HME1 as assayed by soft agar colony
formation assay. Cells received no virus (control, A and
D), adenovirus-expressing
-galactosidase
(Ad-Bgal, B and E), or HME1
(Ad-HME1, C and F) were seeded at
2 × 103 in 0.35% agarose containing Dulbecco's
minimal essential medium with 10% calf serum. Colonies were counted
and photographed 3 weeks later. The representative pictures from four
independent experiments are shown here.

View larger version (16K):
[in a new window]
Fig. 7.
Subcellular localization of CDK2 and CDC2 is
affected by overexpression of 14-3-3 sigma. The NIH3T3 cell lines
were infected with (A-D) or without (E-H)
Ad-HME1. After 48 h, cells were fixed and stained with anti-CDK2
(A and E) or anti-CDC2 antibodies (C
and G) followed by Cy3-conjugated anti-rabbit
immunoglobulin. Nuclei were stained with DAPI dye (B, D, F,
and H).

View larger version (20K):
[in a new window]
Fig. 8.
14-3-3 sigma NES mutant cannot
sequester CDK2 in the cytoplasm. R1b/L17 cells were transfected or
co-transfected with indicated plasmids encoding wt HME1 (FLAG-HME1),
HME1 NES mutant (FLAG-HME1 (NES)), or CDK2 (T7-CDK2). Empty vector
transfection (CMV) was used as controls. After 48 h, cells were
immunostained with anti-FLAG antibody for immunolocalization of HME1
(A, C, and E), or with anti-T7
antibody for immunolocalization of CDK2 (G, I, K, and
M), followed by fluorescein isothiocyanate-conjugated
anti-mouse immunoglobulin. The location of nuclei was indicated by DAPI
staining (B, D, F, H, J, L, and N).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Both authors contributed equally to this work.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sherr, C. J.,
and Roberts, J. M.
(1995)
Genes Dev.
9,
1149-1163
2.
Xiong, Y.,
Hannon, G. J.,
Zhang, H.,
Casso, D.,
Kobayashi, R.,
and Beach, D.
(1993)
Nature
366,
701-704
3.
Harper, J. W.,
Adami, G. R.,
Wei, N.,
Keyomarsi, K.,
and Elledge, S. J.
(1993)
Cell
75,
805-816
4.
El-Deiry, W. S.,
Tokino, T.,
Velculescu, V. E.,
Levy, D. B.,
Parsons, R.,
Trent, J. M.,
Lin, D.,
Mercer, W. E.,
Kinzler, K. W.,
and Vogelstein, B.
(1993)
Cell
75,
817-825
5.
Gu, Y.,
Turck, C. W.,
and Morgan, D. O.
(1993)
Nature
366,
707-710
6.
Toyoshima, H.,
and Hunter, T.
(1994)
Cell
78,
67-74
7.
Polyak, K.,
Lee, M. H.,
Erdjument-Bromage, H.,
Koff, A.,
Roberts, J. M.,
Tempst, P.,
and Massague, J.
(1994)
Cell
78,
59-66
8.
Lee, M. H.,
Reynisdottir, I.,
and Massague, J.
(1995)
Genes Dev.
9,
639-649
9.
Matsuoka, S.,
Edwards, M. C.,
Bai, C.,
Parker, S.,
Zhang, P.,
Baldini, A.,
Harper, J. W.,
and Elledge, S. J.
(1995)
Genes Dev.
9,
650-662
10.
Hannon, G. J.,
and Beach, D.
(1994)
Nature
371,
257-261
11.
Serrano, M.,
Hannon, G. J.,
and Beach, D.
(1993)
Nature
366,
704-707
12.
Guan, K. L.,
Jenkins, C. W.,
Li, Y.,
Nichols, M. A.,
Wu, X.,
O'Keefe, C. L.,
Matera, A. G.,
and Xiong, Y.
(1994)
Genes Dev.
8,
2939-2952
13.
Guan, K. L.,
Jenkins, C. W.,
Li, Y.,
O'Keefe, C. L.,
Noh, S.,
Wu, X.,
Zariwala, M.,
Matera, A. G.,
and Xiong, Y.
(1996)
Mol. Biol. Cell
7,
57-70
14.
Fantl, W. J.,
Muslin, A. J.,
Kikuchi, A.,
Martin, J. A.,
MacNicol, A. M.,
Gross, R. W.,
and Williams, L. T.
(1994)
Nature
371,
612-614
15.
Li, S.,
Janosch, P.,
Tanji, M.,
Rosenfeld, G. C.,
Waymire, J. C.,
Mischak, H.,
Kolch, W.,
and Sedivy, J. M.
(1995)
EMBO J.
14,
685-696
16.
Ford, J. C.,
Al-Khodairy, F.,
Fotou, E.,
Sheldrick, K. S.,
Griffiths, D. J.,
and Carr, A. M.
(1994)
Science
265,
533-535
17.
Aitken, A.,
Collinge, D. B.,
van Heusden, B. P.,
Isobe, T.,
Roseboom, P. H.,
Rosenfeld, G.,
and Soll, J.
(1992)
Trends Biochem. Sci.
17,
498-501
18.
Conklin, D. S.,
Galaktionov, K.,
and Beach, D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7892-7896
19.
Honda, R.,
Ohba, Y.,
and Yasuda, H.
(1997)
Biochem. Biophys. Res. Commun.
230,
262-265
20.
Pallas, D. C.,
Fu, H.,
Haehnel, L. C.,
Weller, W.,
Collier, R. J.,
and Roberts, T. M.
(1994)
Science
265,
535-537
21.
Chen, L.,
Liu, T. H.,
and Walworth, N. C.
(1999)
Genes Dev.
13,
675-685
22.
Lopez-Girona, A.,
Furnari, B.,
Mondesert, O.,
and Russell, P.
(1999)
Nature
397,
172-175
23.
Prasad, G. L.,
Valverius, E. M.,
McDuffie, E.,
and Cooper, H. L.
(1992)
Cell Growth Differ.
3,
507-513
24.
Hermeking, H.,
Lengauer, C.,
Polyak, K.,
He, T. C.,
Zhang, L.,
Thiagalingam, S.,
Kinzler, K. W.,
and Vogelstein, B.
(1997)
Mol. Cell
1,
3-11
25.
Margolis, B.,
Silvennoinen, O.,
Comoglio, F.,
Roonprapunt, C.,
Skolnik, E.,
Ullrich, A.,
and Schlessinger, J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8894-8898
26.
Desai, D.,
Gu, Y.,
and Morgan, D. O.
(1992)
Mol. Biol. Cell
3,
571-582
27.
Kaelin, W. G., Jr.,
Krek, W.,
Sellers, W. R.,
DeCaprio, J. A.,
Ajchenbaum, F.,
Fuchs, C. S.,
Chittenden, T.,
Li, Y.,
Farnham, P. J.,
Blanar, M. A.,
Livingston, D. M.,
and Flemington, E. K.
(1992)
Cell
70,
351-364
28.
Russo, A. A.,
Jeffrey, P. D.,
Patten, A. K.,
Massague, J.,
and Pavletich, N. P.
(1996)
Nature
382,
325-331
29.
Qiu, Y.,
Ravi, L.,
and Kung, H. J.
(1998)
Nature
393,
83-85
30.
Sladeczek, F.,
Camonis, J. H.,
Burnol, A. F.,
and Le Bouffant, F.
(1997)
Mol. Gen. Genet.
254,
571-577
31.
Pines, J.
(1999)
Nature
397,
104-105
32.
Zeng, Y.,
Forbes, K. C.,
Wu, Z.,
Moreno, S.,
Piwnica-Worms, H.,
and Enoch, T.
(1998)
Nature
395,
507-510
33.
Matsuoka, S.,
Huang, M.,
and Elledge, S. J.
(1998)
Science
282,
1893-1897
34.
Muslin, A. J.,
Tanner, J. W.,
Allen, P. M.,
and Shaw, A. S.
(1996)
Cell
84,
889-897
35.
Yaffe, M. B.,
Rittinger, K.,
Volinia, S.,
Caron, P. R.,
Aitken, A.,
Leffers, H.,
Gamblin, S. J.,
Smerdon, S. J.,
and Cantley, L. C.
(1997)
Cell
91,
961-971
36.
Peng, C. Y.,
Graves, P. R.,
Thoma, R. S.,
Wu, Z.,
Shaw, A. S.,
and Piwnica-Worms, H.
(1997)
Science
277,
1501-1505
37.
Sanchez, Y.,
Wong, C.,
Thoma, R. S.,
Richman, R.,
Wu, Z.,
Piwnica-Worms, H.,
and Elledge, S. J.
(1997)
Science
277,
1497-1501
38.
Dellambra, E.,
Patrone, M.,
Sparatore, B.,
Negri, A.,
Ceciliani, F.,
Bondanza, S.,
Molina, F.,
Cancedda, F. D.,
and De Luca, M.
(1995)
J. Cell Sci.
108,
3569-3579
39.
Vellucci, V. F.,
Germino, F. J.,
and Reiss, M.
(1995)
Gene (Amst.)
166,
213-220
40.
Porter, P. L.,
Malone, K. E.,
Heagerty, P. J.,
Alexander, G. M.,
Gatti, L. A.,
Firpo, E. J.,
Daling, J. R.,
and Roberts, J. M.
(1997)
Nat. Med.
3,
222-225
41.
Loda, M.,
Cukor, B.,
Tam, S. W.,
Lavin, P.,
Fiorentino, M.,
Draetta, G. F.,
Jessup, J. M.,
and Pagano, M.
(1997)
Nat. Med.
3,
231-234
42.
Catzavelos, C.,
Bhattacharya, N.,
Ung, Y. C.,
Wilson, J. A.,
Roncari, L.,
Sandhu, C.,
Shaw, P.,
Yeger, H.,
Morava-Protzner, I.,
Kapusta, L.,
Franssen, E.,
Pritchard, K. I.,
and Slingerland, J. M.
(1997)
Nat. Med.
3,
227-230
43.
Nakayama, K.,
Ishida, N.,
Shirane, M.,
Inomata, A.,
Inoue, T.,
Shishido, N.,
Horii, I.,
Loh, D. Y.,
and Nakayama, K.
(1996)
Cell
85,
707-720
44.
Ragnarsson, G.,
Eiriksdottir, G.,
Johannsdottir, J. T.,
Jonasson, J. G.,
Egilsson, V.,
and Ingvarsson, S.
(1999)
Br. J. Cancer
79,
1468-1474
45.
Hilgers, W.,
Tang, D. J.,
Sugar, A. Y.,
Shekher, M. C.,
Hruban, R. H.,
and Kern, S. E.
(1999)
Genes Chromosomes Cancer
24,
351-355
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
U. K. Bhawal, M. Sugiyama, Y. Nomura, H. Kuniyasu, and K. Tsukinoki Loss of 14-3-3 Sigma Protein Expression and Presence of Human Papillomavirus Type 16 E6 in Oral Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, October 1, 2008; 134(10): 1055 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. A. Moreira, T. Shen, G. Ohlsson, P. Gromov, I. Gromova, and J. E. Celis A Combined Proteome and Ultrastructural Localization Analysis of 14-3-3 Proteins in Transformed Human Amnion (AMA) Cells: Definition of A Framework to Study Isoform-Specific Differences Mol. Cell. Proteomics, July 1, 2008; 7(7): 1225 - 1240. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-L. Cheng, W.-G. Huang, Z.-C. Chen, F. Peng, P.-F. Zhang, M.-Y. Li, F. Li, J.-L. Li, C. Li, H. Yi, et al. Identification of Novel Nasopharyngeal Carcinoma Biomarkers by Laser Capture Microdissection and Proteomic Analysis Clin. Cancer Res., January 15, 2008; 14(2): 435 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Marinova, S. Han, and B. Zheng Human germinal center T cells are unique Th cells with high propensity for apoptosis induction Int. Immunol., August 1, 2006; 18(8): 1337 - 1345. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Han, H. Xie, Q. Chen, and J.-T. Zhang Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}. Mol. Cancer Ther., April 1, 2006; 5(4): 903 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yang, Y.-Y. Wen, R. Zhao, Y.-L. Lin, K. Fournier, H.-Y. Yang, Y. Qiu, J. Diaz, C. Laronga, and M.-H. Lee DNA Damage-Induced Protein 14-3-3 {sigma} Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer. Cancer Res., March 15, 2006; 66(6): 3096 - 3105. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, H. Liu, B. Han, and J.-T. Zhang Identification of 14-3-3{sigma} as a Contributor to Drug Resistance in Human Breast Cancer Cells Using Functional Proteomic Analysis. Cancer Res., March 15, 2006; 66(6): 3248 - 3255. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wood and A. Shilatifard Transcriptional blackjack with p21. Genes & Dev., March 15, 2006; 20(6): 643 - 647. [Full Text] [PDF] |
||||
![]() |
H. Yang, R. Zhao, and M.-H. Lee 14-3-3{sigma}, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol. Cancer Ther., February 1, 2006; 5(2): 253 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Benzinger, N. Muster, H. B. Koch, J. R. Yates III, and H. Hermeking Targeted Proteomic Analysis of 14-3-3{varsigma}, a p53 Effector Commonly Silenced in Cancer Mol. Cell. Proteomics, June 1, 2005; 4(6): 785 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Perathoner, D. Pirkebner, G. Brandacher, G. Spizzo, S. Stadlmann, P. Obrist, R. Margreiter, and A. Amberger 14-3-3{sigma} Expression Is an Independent Prognostic Parameter for Poor Survival in Colorectal Carcinoma Patients Clin. Cancer Res., May 1, 2005; 11(9): 3274 - 3279. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. A. Moreira, G. Ohlsson, F. E. Rank, and J. E. Celis Down-regulation of the Tumor Suppressor Protein 14-3-3{sigma} Is a Sporadic Event in Cancer of the Breast Mol. Cell. Proteomics, April 1, 2005; 4(4): 555 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kino, A. Gragerov, A. Valentin, M. Tsopanomihalou, G. Ilyina-Gragerova, R. Erwin-Cohen, G. P. Chrousos, and G. N. Pavlakis Vpr Protein of Human Immunodeficiency Virus Type 1 Binds to 14-3-3 Proteins and Facilitates Complex Formation with Cdc25C: Implications for Cell Cycle Arrest J. Virol., March 1, 2005; 79(5): 2780 - 2787. [Abstract] [Full Text] [PDF] |
||||
|
|